BioSpace News Archive

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC) in EU country Latvia.

TriSalus Life Sciences® Inc. announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer 38th Annual Meeting being held November 1-5, 2023, in San Diego, California.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and FibroFighters, a patient-centric advocacy and education organization dedicated to helping patients and caregivers affected by Fibrolamellar Carcinoma, have announced a collaboration to advance clinical care for FLC patients.

LivaNova PLC announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present a general business update during fireside chats at two healthcare conferences in New York in November.

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company’s proposal to harmonize clinical trial designs in the U.S. and Canada for an ongoing Phase 3 study of EB05 (paridiprubart).

Plus Therapeutics, Inc. announced that it will present four posters and one oral presentation at the Society for NeuroOncology 28th Annual Meeting being held November 15-19, 2023 in Vancouver, Canada.

Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus platform, has presented data showing the potential as well as the versatility of Secarna’s LNA-modified ASOs.

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2023 on Wednesday, Nov. 1 at 9 a.m., ET.

Regen BioPharma, Inc. has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2023, before the US markets open on Wednesday, November 8, 2023